Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies
| dc.contributor.author | Wischik, Claude M | |
| dc.contributor.author | Wischik, Damon J | |
| dc.contributor.author | Storey, John M D | |
| dc.contributor.author | Harrington, Charles R | |
| dc.contributor.editor | Martinez, Ana | |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Chemistry | en |
| dc.date.accessioned | 2014-12-03T11:01:01Z | |
| dc.date.available | 2014-12-03T11:01:01Z | |
| dc.date.issued | 2010 | |
| dc.format.extent | 23 | |
| dc.format.extent | 1546681 | |
| dc.identifier | 14419807 | |
| dc.identifier | 001dbfca-e6eb-420d-a7b6-8e674faba32b | |
| dc.identifier | 85057775434 | |
| dc.identifier.citation | Wischik, C M, Wischik, D J, Storey, J M D & Harrington, C R 2010, Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. in A Martinez (ed.), Emerging drugs and targets for Alzheimer's disease : Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. vol. 1, RSC Drug Discovery Series, Cambridge, pp. 210-232. https://doi.org/10.1039/9781849731065 | en |
| dc.identifier.doi | 10.1039/9781849731065 | |
| dc.identifier.isbn | 978-1-84973-106-5 | |
| dc.identifier.other | ORCID: /0000-0002-5261-5467/work/73579127 | |
| dc.identifier.other | ORCID: /0000-0003-2250-3920/work/47672896 | |
| dc.identifier.uri | http://hdl.handle.net/2164/4066 | |
| dc.identifier.vol | 1 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Emerging drugs and targets for Alzheimer's disease | en |
| dc.relation.ispartofseries | RSC Drug Discovery Series | en |
| dc.subject | RM Therapeutics. Pharmacology | en |
| dc.subject.lcc | RM | en |
| dc.title | Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies | en |
| dc.type | Book item | en |